---
title: "Biokin Pharmaceutical Gets Nod to Trial Solid Tumor Drug"
date: "2025-02-10 12:15:59"
summary: "Sichuan Biokin Pharmaceutical will conduct the phase III clinical trial on the drug, BL-M07D1 (HER2-ADC) for injection, after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Saturday. The drug will be tested on patients with various HER2-expressing/mutated solid tumors, including non-small cell lung..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Sichuan Biokin Pharmaceutical will conduct the phase III clinical trial on the drug, BL-M07D1 (HER2-ADC) for injection, after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Saturday.

The drug will be tested on patients with various HER2-expressing/mutated solid tumors, including non-small cell lung cancer, breast cancer, urothelial carcinoma, gynecological tumors and digestive tract tumors, the disclosure said.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250209:G2465396:0/)
